Evidence map›Paper›PMID 36712515›Full record

ArticleFrontiers in nutrition2022

Impact of COVID-19 pandemic on the PREDIMED-Plus randomized clinical trial: Effects on the interventions, participants follow-up, and adiposity.

Indira Paz-Graniel, Montserrat Fitó, Emilio Ros, Pilar Buil-Cosiales, Dolores Corella, Nancy Babio, J Alfredo Martínez, Ángel M Alonso-Gómez, Julia Wärnberg, Jesús Vioque and 37 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

47 authors at 19 institutions in 3 countries.

Indira Paz-GranielConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Montserrat FitóConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Emilio RosConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Pilar Buil-CosialesConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Dolores CorellaConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Nancy BabioConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
J Alfredo MartínezConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Ángel M Alonso-GómezConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Julia WärnbergConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Jesús VioqueCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, España.
Dora RomagueraConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
José López-MirandaConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Ramon EstruchConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Francisco J TinahonesConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
José LapetraConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Lluis Serra-MajemConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Aurora Bueno-CavanillasCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, España.
Josep A TurConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Vicente Martín-SánchezCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, España.
Xavier PintóConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
José Juan GaforioCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, España.
Pilar Matía-MartínConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Josep VidalConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Clotilde VázquezConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Lidia DaimielConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Jesus F García-GavilánConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Estefanía ToledoConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Stephanie K NishiConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Jose V SorlíConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Olga CastañerConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Antonio García-RíosConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Manoli García de la HeraCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, España.
Francisco Javier Barón-LópezConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Miguel Ruiz-CanelaConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Marga MoreyConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Rosa CasasConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Eva María Garrido-GarridoPrimary Care Center Zaidín-Center, Andalusian Health Service, Granada, Spain.
Lucas Tojal-SierraConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
José C Fernández-GarcíaConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Zenaida Vázquez-RuizConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Rebeca Fernández-CarriónConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Albert GodayConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Patricia J Peña-OrihuelaConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Laura Compañ-GabucioCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, España.
Helmut SchröderUnit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d'Investigació Médica (IMIM), Barcelona, Spain.
Miguel A Martínez-GonzalezConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Jordi Salas-SalvadóConsorcio CIBER, Fisiopatología de la Obesidad y Nutrición (CIBERObn), Institute of Health Carlos III, Madrid, Spain.
Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition · ESInstituto de Salud Carlos III · ESCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESHospital Universitario Araba · ESInstitut d'Investigació Sanitària Pere Virgili · ESInstituto Maimónides de Investigación Biomédica de Córdoba · ESUniversitat de Barcelona · ESAgencia de Evaluación de Tecnologías Sanitarias · ESAndalusian Health Service · ESHealth Research Institute of the Balearic Islands · ESHospital Universitario Fundación Jiménez Díaz · ESHospital Universitario Insular de Gran Canaria · ESIMDEA Food · ESInstituto de Investigación Biomédica de Málaga · ESInstituto de investigación sanitaria y biomédica de AlicanteUniversidad de León · ESUniversidad de Málaga · ESUniversidad Rovira i Virgili · ESUniversitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The COVID-19 pandemic has affected the implementation of most ongoing clinical trials worldwide including the PREDIMED-Plus study. The PREDIMED-Plus is an ongoing, multicenter, controlled intervention trial, aimed at weight-loss and cardiovascular disease prevention, in which participants were randomized (1:1 ratio) to an intervention group (energy-reduced Mediterranean diet, promotion of physical activity, and behavioral support) or to a control group (Mediterranean diet with usual care advice). When the pandemic began, the trial was in the midst of the planned intervention. The objective of this report was to examine the effects of the pandemic on the delivery of the intervention and to describe the strategies established to mitigate the possible adverse effects of the pandemic lockdown on data collection and adiposity. Methods: We assessed the integrity of the PREDIMED-Plus trial during 5 identified periods of the COVID-19 pandemic determined according to restrictions dictated by the Spanish government authorities. A standardized questionnaire was delivered to each of the 23 PREDIMED-Plus recruiting centers to collected data regarding the trial integrity. The effect of the restrictions on intervention components (diet, physical activity) was evaluated with data obtained in the three identified lockdown phases: pre lockdown, lockdown proper, and post lockdown. Results: During the lockdown (March/2020-June/2021), 4,612 participants (48% women, mean age 65y) attended pre-specified yearly follow-up visits to receive lifestyle recommendations and obtain adiposity measures. The overall mean (SD) of the proportions reported by each center showed that 40.4% (25.4) participants had in-person visits, 39.8% (18.2) participants were contacted by telephone and 35% (26.3) by electronic means. Participants' follow-up and data collection rates increased across lockdown periods (from ≈10% at onset to ≈80% at the end). Compared to pre-lockdown, waist circumference increased during (0.75 cm [95% CI: 0.60-0.91]) and after (0.72 cm [95% CI: 0.56-0.89]) lockdown. Body weight did not change during lockdown (0.01 kg [95% CI: -0.10 to 0.13) and decreased after lockdown (-0.17 kg [95% CI: -0.30 to -0.04]). Conclusion: Mitigating strategies to enforce the intervention and patient's follow-up during lockdown have been successful in preserving the integrity of the trial and ensuring its continuation, with minor effects on adiposity. Clinical trial registration: https://doi.org/10.1186/ISRCTN89898870, identifier ISRCTN89898870.

Indexed as

clinical trialCOVID-19lockdownMediterraean dietPREDIMED-Plusweight-loss

Identifiers

PMID36712515
PMCPMC9878159
OpenAlexW4315641285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.